Merus N.V. (MRUS) subject to Genmab tender offer at $97 per share
Rhea-AI Filing Summary
Merus N.V. reports insider activity tied to a change in control transaction. The company previously entered into a Transaction Agreement with Genmab A/S and its wholly owned subsidiary, which commenced a tender offer for all issued and outstanding Merus common shares. On December 12, 2025, the purchaser accepted all Shares that were validly tendered and not properly withdrawn at an all-cash price of $97.00 per share, without interest and less applicable withholding taxes, to be paid as soon as practicable after the acceptance time.
In connection with this transaction, multiple employee share options held by Merus’s Chief Financial Officer & PFO, each a right to buy common shares at exercise prices such as $41.65, $36.09, $26.5, $16.09 and $10.04 per share, were cancelled on December 12, 2025. For each option, the holder will receive cash equal to the amount by which the $97.00 Offer Consideration exceeds the option’s exercise price, multiplied by the number of Shares underlying that option, and the form shows 0 derivative securities beneficially owned after these transactions.
Positive
- None.
Negative
- None.
Insights
Genmab’s $97 cash tender offer for Merus triggers a cash-out of the CFO’s stock options.
The disclosure shows that Genmab A/S, through a wholly owned subsidiary, launched a tender offer for all issued and outstanding Merus N.V. common shares. As of December 12, 2025, the purchaser accepted all Shares that were validly tendered and not properly withdrawn at an all-cash price of $97.00 per share, without interest and less applicable withholding taxes, to be paid as soon as practicable after the acceptance time.
The reporting person is Merus’s Chief Financial Officer & PFO, whose share options are listed in Table II as share options (rights to buy) with exercise prices such as $41.65, $36.09, $26.5, $16.09 and $10.04 per share, each linked to a specific number of underlying common shares. Footnote 2 states that each option was cancelled under the Transaction Agreement in exchange for cash equal to the amount by which the $97.00 Offer Consideration exceeds the applicable exercise price per Share, multiplied by the aggregate number of Shares underlying that option.
After these cancellations, the table shows 0 derivative securities beneficially owned, indicating that the CFO no longer holds these options. From an investor perspective, this reflects the mechanics of a cash tender offer where equity and equity-based awards are settled in cash at a defined price, rather than signaling a discretionary insider sale; the overall impact on shareholders is driven by the $97.00 per Share consideration rather than by this individual insider’s form.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Share Option (right to buy) | 100,000 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 107,300 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 372,924 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 14,414 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 16,604 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 6,120 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 8,631 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 17,000 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 5,650 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 4,983 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 8,500 | $0.00 | -- |
Footnotes (1)
- On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
FAQ
What major transaction involving Merus N.V. (MRUS) is described?
The content describes a Transaction Agreement under which a wholly owned subsidiary of Genmab A/S commenced a tender offer for all issued and outstanding Merus N.V. common shares, with the purchaser accepting all Shares that were validly tendered and not properly withdrawn.
How were the Merus N.V. (MRUS) CFOs stock options treated in this transaction?
Each share option held by the Chief Financial Officer & PFO was cancelled pursuant to the Transaction Agreement in exchange for cash equal to the product of (i) the amount by which the $97.00 Offer Consideration exceeds the applicable exercise price per Share and (ii) the aggregate number of Shares underlying that option.
What types of derivative securities are reported for the Merus N.V. (MRUS) insider?
The filing lists multiple share options (rights to buy) as derivative securities, each tied to Merus common shares with exercise prices including $41.65, $36.09, $26.5, $23.29, $18.56, $16.09, $13.35 and $10.04 per share, and each now showing 0 derivative securities beneficially owned after cancellation.
Who is the reporting person in this Merus N.V. (MRUS) insider filing and what is their role?
The reporting person is identified as an officer of Merus N.V., with the title Chief Financial Officer & PFO, and the form is filed by one reporting person.